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Received 26 March 2008; accepted 26 March 2008Last year, several landmark studies reported that reprogram-
ming of cultured human fibroblasts, by simple transduction of a
few key transcription factors, could convert them into pluri-
potent stem cell lines (induced pluripotent stem or iPS cells)
very similar to embryo-derived stemcells (for reviews see Pera,
2008 and Pera andHasegawa, 2008). These amazing discoveries
have opened up dazzling new prospects for stem cell research
and regenerative medicine. The ensuing excitement notwith-
standing, there is some way to go before this approach is
applied to the production of pluripotent cell lines for clinical
use. All the protocols used to date involve random integration
of viral constructs into the host genome, and in some reports,
iPS cells from postnatal human fibroblasts proved difficult to
obtain or showed apparent defects in differentiation. Thus, it is
important to gain a better understanding of the mechanisms of
cellular reprogramming, to guide efforts to develop simpler and
moreefficientmeans of deriving iPS cells. It is also important to
determine for certain whether iPS cell lines derived from
human postnatal sources are really equivalent to normal
embryonic stem (ES) cells. In this issue of Stem Cell Research,
Masaki and colleagues (Masaki et al., 2007) provide strong
confirmation that human neonatal fibroblasts can be converted
to iPS cells without accumulation of genetic changes (apart
from those caused by integration of the constructs used in the
protocol). This study also yields new insights into how cells
respond to reprogramming factors, through its analysis of gene
expression during the generation of iPS cells.
Masaki et al. transduced human cDNAs of the original set of
reprogramming genes first described by Yamanaka (Takahashi
and Yamanaka, 2006) (POU5F1, SOX2, KLF4, and CMYC) into
postnatal fibroblasts. By a process of morphological selection
(below) they obtained iPS cell lines at a frequency of 0.01–E-mail address: pera@usc.edu.
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doi:10.1016/j.scr.2008.03.0020.001% of the starting fibroblast population. These iPS lines
were very similar to ES cells in their expression of cell surface
markers and in their genome-wide transcriptional profiles, and
they gave rise to teratomas as xenografts in immunodeprived
mice. As expected, the Oct-4 and Sox-2 loci were demethy-
lated in the iPS lines compared to the fibroblast parent cells.
The iPS cell lines maintained a diploid karyotype, and signi-
ficantly, genome-wide single-nucleotide polymorphism analy-
sis did not reveal any submicroscopic genetic changes in the
reprogrammed lines. This findings provide convincing further
evidence that genetic alteration is not required for establish-
ment or progressive growth of human iPS cell lines, even in
chemically defined media.
In their studies, Masaki et al. undertook an informative
analysis of growing colonies at an early stage of the repro-
gramming process. The team carried out alkaline phosphatase
staining and morphological examination on colonies emerging
after transduction and then checked for expression of eight
pluripotency genes by quantitative reverse transcriptase-
polymerase chain reaction. The eight genes were chosen on
the basis of their consistent expression in human ES cells
(Adewumi et al., 2007). Some represent archetypal pluripo-
tency genes, expressed only in pluripotent cells; others are
consistently present in pluripotent cells but are transcribed in
other cell types as well. There was clear evidence for partial
reprogramming of gene expression in many colonies, and
indeed, only a small minority of colonies expressed all plu-
ripotency-associated genes.However, themajority of colonies,
even those with fibroblast morphology, expressed nanog,
TDGF1, and DNMT3b, the archetypal pluripotency genes. Ex-
pression of these core pluripotency genes thus appears in-
sufficient to guarantee complete reprogramming. The authors
did note a consistent morphological phenotype associatedwith
expression of all eight pluripotency-associated genes analyzed,.
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further expansion, they were able to isolate iPS cells. It does
appear from this and other studies (e.g., Meissner et al., 2007)
that even in the post-genomic systems biology world, the
bright-field and phase-contrast microscopes remain as remark-
ably useful tools for the study of cell differentiation.
It is possible that the variation in expression of pluripotency
genes among colonies transduced with reprogramming factors
reflects a variable response within a homogeneous cell
population. Alternately, specific subpopulations of cells within
fibroblast cultures may respond differently to reprogramming
protocols. Currently it is not possible to distinguish between
these alternatives.Whatever the cause of the variation in gene
expression in the emerging colonies, it might be possible to
exploit these findings to improve selection or screening for
reprogrammed cells. For example, if expression of certain
pluripotency-associated genes that perhaps lie downstream of
the core regulatory network of Oct-4, Sox-2, and nanog, for
example TERT, is more strongly associated with complete
reprogramming, perhaps these downstream genes should be
the focus of strategies for screening or selection of iPS cells.
Molecular dissection of the reprogramming process
remains challenging, due to low efficiencies involved, and
the data of Masaki et al. did not prospectively establish the
fate of cells expressing different combinations of pluripo-
tency genes. However, examination of the dynamics of
reprogramming is clearly providing some interesting and
sometimes surprising insights. For example, a recent study in
the mouse showed that the earliest changes during fibroblast
reprogramming in this species involved silencing of fibroblast
genes, and activation of expression of the ES cell surface
marker SSEA-1, rather than induction of expression of plu-
ripotency genes, which took place later in the process
(Stadtfeld et al., 2008). SSEA-1 is a cell surface carbohy-
drate, first described over 30 years ago (Solter and Knowles,
1978), whose function in pluripotent cells is unknown andwhose expression in ES cells is species specific; it is a little
surprising that its appearance should be one of the earliest
harbingers of reprogramming. The recent work of Stadtfeld
et al. and Masaki and coworkers suggests we have a good deal
more to learn about booting the differentiated epigenome
back to the embryonic state. Deeper inquiry is certain to
yield new insights into the molecular control of pluripotency
and will light the ways toward refinement of iPS technology
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